Viamet Pharmaceuticals specializes in discovering and developing top-notch inhibitors of metalloenzymes using their unique Metallophile™ Technology. This disruptive approach allows them to identify high-potential therapeutic targets, optimize existing inhibitors, and efficiently generate patentable small molecule compounds. Their focus areas include invasive fungal infections, cancer, cardiovascular diseases, and orphan diseases. With a strong foundation in metalloenzyme chemistry and biology, Viamet aims to deliver breakthrough therapies with superior safety and efficacy profiles, addressing the critical needs of patients and clinicians.